AtulKumarSinghalMD

Rheumatology • Mesquite, TX

Physician

Join to view full profile

Dr. Singhal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Singhal's full profile

Already have an account?

Office
1600 Republic Pkwy
Ste 200
Mesquite, TX 75150
Phone+1 972-288-2600

Fax+1 972-288-8886
Is this information wrong?

Education & Training

University of Pennsylvania Health SystemFellowship, Rheumatology, 1992 - 1995
Stony Brook Medicine/University HospitalResidency, Internal Medicine, 1989 - 1992
All India Institute of Medical SciencesClass of 1987

Certifications & Licensure

TX State Medical License 1995 - 2024
NJ State Medical License 1994 - 1997
PA State Medical License 1992 - 1996

Awards, Honors, & Recognition

Fellow (FACR) American College of Rheumatology

Clinical Trials

Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen Start of enrollment: 2006 Oct 04
Completed
Phase 4
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT) Start of enrollment: 2007 May 15
Terminated
Phase 3
Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis Start of enrollment: 2007 Mar 01
Completed
Phase 2
Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients Start of enrollment: 2008 Nov 01
Completed
Phase 2
A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors Start of enrollment: 2011 Aug 02
Completed
Phase 4
A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis Start of enrollment: 2011 Jul 26
Completed
Phase 4
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX Start of enrollment: 2013 Nov 07
Completed
Phase 3
Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care Start of enrollment: 2016 Jun 01
Recruiting
Not Applicable
Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment Start of enrollment: 2016 Jul 27
Completed
Phase 3
Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy Start of enrollment: 2016 Aug 08
Completed
Phase 3
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Start of enrollment: 2016 Aug 30
Completed
Phase 3
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy Start of enrollment: 2016 Dec 22
Terminated
Phase 2
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis Start of enrollment: 2017 Feb 28
Active, not recruiting
Phase 3
A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE) Start of enrollment: 2018 Nov 26
Completed
Phase 1
Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Start of enrollment: 2019 Apr 01
Completed
Phase 2
A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy Start of enrollment: 2019 May 07
Completed
Phase 2
Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus Start of enrollment: 2019 Mar 26
Active, not recruiting
Phase 2
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy Start of enrollment: 2019 Dec 03
Terminated
Phase 3
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy Start of enrollment: 2019 Nov 13
Terminated
Phase 3
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis Start of enrollment: 2020 Jan 07
Completed
Phase 2
A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis Start of enrollment: 2020 Aug 10
Active, not recruiting
Phase 3
Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA Start of enrollment: 2020 Mar 16
Completed
Phase 2
A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy Start of enrollment: 2020 Aug 18
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

2 citations
Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis.
David Gordon, Alan Kivitz, Atul Singhal, David Burt, Madison C Bangs, Emma E Huff, Heidi Rath Hope, Joseph B Monahan> ;ACR Open Rheumatology. 2023 Feb 1
1 citations
Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to ...
Roy Fleischmann, Alan Friedman, Edit Drescher, Atul Singhal, Gregorio Cortes-Maisonet, Thao Doan, Wenjing Lu, Zailong Wang, Ahmed Nader, William Housley, Stanley Cohen...> ;The Lancet. Rheumatology. 2022 Jun 1
5 citations
Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with conco...
Peter Nash, Philip J. Mease, Bruce Kirkham, Atul Singhal, Erhard Quebe-Fehling, Luminita Pricop, Corine Gaillez> ;Clinical and Experimental Rheumatology. 2021 Sep 3
18 citations
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results f...
Philip J. Mease, Robert Landewé, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra V. Navarra, Aimee Readie, Shephard Mpofu, Eumorphia Maria Delicha, Lu...> ;RMD Open. 2021 Jul 1
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S, FUTURE 1 Study Group> ;The New England journal of medicine.
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, MEASURE 1 Study Group, MEASURE 2 Stu...> ;The New England journal of medicine.
190 citations
Yoga-Based Intervention for Carpal Tunnel Syndrome: A Randomized Trial
Singhal A, Katz Wa, Allan Da, R. A. Reshetar, Schumacher Hr, M. S. Garfinkel> ;JAMA. 1998 Nov 11
38 citations
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
Désirée van der Heijde, Philip J. Mease, Robert Landewé, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra V. Navarra, Xuan Zhu, Gregory Ligozio, Aimee ...> ;Rheumatology. 2020 Jun 1
Secukinumab Improves Active Psoriatic Arthritis Symptoms and Inhibits Radiographic Progression: Primary Results from the Randomised, Double-Blind, Phase III FUTURE 5 S...
Atul Singhal, Philip Mease> ;Emergency Medicine Journal. 2018 Mar 20
278 citations
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): ...
Roy Fleischmann, Eduardo Mysler, Stephen Hall, Alan J Kivitz, Robert J. Moots, Zhen Luo, Ryan DeMasi, Koshika Soma, Richard Zhang, Liza Takiya, Svitlana Tatulych, Chri...> ;Lancet. 2017 Jul 29
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3...
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M,...> ;Lancet (London, England). 2015-06-28
206 citations
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
David L. Boyle, Koshika Soma, Jennifer Hodge, A. Kavanaugh, D Mandel, Philip J. Mease, R Shurmur, A K Singhal, Nathan Wei, Sanna Rosengren, Irina Kaplan, Sriram Krishn...> ;Annals of the Rheumatic Diseases. 2013 Jun 1
460 citations
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Cem Gabay, Paul Emery, Ronald F van Vollenhoven, Ara Dikranian, Rieke Alten, Karel Pavelka, Micki Klearman, David Musselman, Sunil Agarwal, Jennifer Green, Arthur Kava...> ;Lancet. 2013 May 4
37 citations
The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis
Karen E. Hansen, John J. Cush, A. Singhal, David A Cooley, Stanley N. Cohen, S. R. Patel, Mark C. Genovese, S. Sundaramurthy, Michael Schiff> ;Arthritis and Rheumatism. 2004 Apr 15
Join now to see all

Professional Memberships

American College of Rheumatology - ACR
Fellow

Hospital Affiliations

Medical City DallasDallas, Texas
Texas Health Presbyterian Hospital DallasDallas, Texas
Baylor Scott & White Medical Center - PlanoPlano, Texas

AtulKumarSinghalMD

Dr. Singhal is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Professional Memberships

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.